MktsMarkets

RenovoRx, Inc.
NASDAQ: RNXTKey statistics
RNXT News
Stories mentioning RNXT from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 563.00 | 238.00 | 266.00 | 422.00 | 197.00 | |||
| Cost of Goods Sold | 84.00 | 28.00 | 53.00 | 152.00 | 94.00 | |||
| Gross Profit | 479.00 | 210.00 | 213.00 | 270.00 | 103.00 | 43.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 1,228 | 1,516 | 1,685 | 1,426 | 1,642 | 1,576 | 1,650 | 1,542 |
| Sales General & Admin | 2,720 | 2,216 | 1,728 | 1,522 | 1,571 | 1,099 | 1,178 | 1,492 |
| Total Operating Expenses | 3,948 | 3,732 | 3,413 | 2,948 | 3,213 | 2,675 | 2,828 | 3,034 |
| Operating Income (Loss) | (3,469) | (3,522) | (3,200) | (2,678) | (3,110) | (2,632) | (2,828) | (3,034) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 0.00 | ||||||
| Net Income (Loss) | (3,521) | (2,941) | (2,912) | (2,895) | (2,420) | (2,878) | (2,471) | (2,389) |
| Earnings Per Share (Basic) | (0.09) | (0.08) | (0.08) | (0.08) | (0.08) | (0.13) | (0.10) | (0.10) |
| Earnings Per Share (Diluted) | (0.09) | (0.08) | (0.08) | (0.08) | (0.08) | (0.13) | (0.10) | (0.10) |
| Weighted Average Shares Outstanding (Basic) | 38,032 | 35,333 | 36,646 | 36,577 | 31,396 | 22,271 | 24,941 | 24,049 |
| Weighted Average Shares Outstanding (Diluted) | 38,032 | 35,333 | 36,646 | 36,577 | 31,396 | 22,271 | 24,941 | 24,049 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About RNXT
RenovoRx, Inc. (NASDAQ: RNXT) is a stock listed on the Nasdaq Stock Market under the ticker symbol RNXT. It last traded at $1.18 (Nov 10, 2026, 4:00 PM ET), unchanged on the day. That gives RenovoRx a market capitalisation of $56.9M.
Over the past 52 weeks RNXT has traded between $0.7000 and $2.59.
Revenue for the quarter ended Mar 31, 2026 was $563.0K; a net loss of $3.5M. Revenue was up 186% from $197.0K in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $563.0K | -$3.5M | -625.4% |
| Dec 31, 2025 | $238.0K | -$2.9M | -1235.7% |
| Sep 30, 2025 | $266.0K | -$2.9M | -1094.7% |
| Jun 30, 2025 | $422.0K | -$2.9M | -686.0% |
From RenovoRx’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…